相似文献
1
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.
Curr Oncol Rep. 2024 Sep;26(9):1120-1133. doi: 10.1007/s11912-024-01570-1. Epub 2024 Jul 2.
2
Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.
Int J Mol Sci. 2024 Jun 27;25(13):7056. doi: 10.3390/ijms25137056.
3
Immunotherapy for Non-melanoma Skin Cancer.
Curr Oncol Rep. 2021 Aug 27;23(11):125. doi: 10.1007/s11912-021-01120-z.
4
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005082.
5
High-Risk Non-Melanoma Skin Cancers: Biological and Therapeutic Advances.
Hematol Oncol Clin North Am. 2024 Oct;38(5):1071-1085. doi: 10.1016/j.hoc.2024.05.004. Epub 2024 Jun 21.
6
Non-Melanoma Skin Cancers: Biological and Clinical Features.
Int J Mol Sci. 2020 Jul 29;21(15):5394. doi: 10.3390/ijms21155394.
7
The Landmark Series: Non-melanoma Skin Cancers.
Ann Surg Oncol. 2020 Jan;27(1):22-27. doi: 10.1245/s10434-019-07831-9. Epub 2019 Sep 23.
8
Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Crit Rev Oncol Hematol. 2022 Dec;180:103855. doi: 10.1016/j.critrevonc.2022.103855. Epub 2022 Oct 17.
9
Updates in the Management of Advanced Nonmelanoma Skin Cancer.
Surg Oncol Clin N Am. 2024 Oct;33(4):723-733. doi: 10.1016/j.soc.2024.04.006. Epub 2024 Jun 5.
10
Adjuvant and Neoadjuvant Treatment of Skin Cancer.
Facial Plast Surg Clin North Am. 2019 Feb;27(1):139-150. doi: 10.1016/j.fsc.2018.08.014.
本文引用的文献
1
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
J Clin Oncol. 2024 Mar 20;42(9):1011-1020. doi: 10.1200/JCO.23.01497. Epub 2024 Jan 22.
2
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
J Clin Oncol. 2024 Mar 20;42(9):1021-1030. doi: 10.1200/JCO.23.01498. Epub 2024 Jan 22.
3
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18.
4
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007637.
5
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
J Am Acad Dermatol. 2024 Feb;90(2):414-418. doi: 10.1016/j.jaad.2023.08.111. Epub 2023 Oct 14.
6
Cost of skin cancer-related dermatological care is higher in transplant recipients compared with nonimmunosuppressed patients.
J Am Acad Dermatol. 2024 Jan;90(1):150-152. doi: 10.1016/j.jaad.2023.08.077. Epub 2023 Sep 4.
7
Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
Ophthalmic Plast Reconstr Surg. 2024;40(1):1-10. doi: 10.1097/IOP.0000000000002464. Epub 2023 Aug 8.
8
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11.
9
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
Crit Rev Oncol Hematol. 2023 Sep;189:104066. doi: 10.1016/j.critrevonc.2023.104066. Epub 2023 Jul 11.
10
Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma.
J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1318-e1320. doi: 10.1111/jdv.19307. Epub 2023 Jul 11.
Zotero 插件